Kymera Therapeutics
@KymeraTx • 3,531 subscribers
Advancing the field of targeted protein degradation to deliver breakthrough medicines for previously untreatable diseases
Shorts
Videos
Our team came together for a lively après‑ski celebration to wrap up another year of teamwork, progress, and big accomplishments!🎿❄️ With curling showdowns, DIY snow globes, and well‑earned toasts, the night was filled with winter‑wonderland fun.🥌 A huge thank you to every Kymerian whose dedication and collaboration propels our mission to advance transformative medicines for patients. Wishing everyone a joyful holiday season!✨ #Culture #Belong #HappyHolidays
Kymera Therapeutics50,901 次观看 • 9 个月前
Today, we announced the completion of enrollment in our global BROADEN2 Phase 2b trial of KT-621, our investigational, first-in-class, oral STAT6 degrader, in atopic dermatitis, nearly six months ahead of anticipated timelines. This milestone enables us to accelerate our expected topline data readout to year-end 2026 and continue advancing KT-621 as a potential oral treatment option for patients living with atopic dermatitis and other Type 2 inflammatory diseases. Read more in our press release:
Kymera Therapeutics21,541 次观看 • 3 个月前
We’re excited to announce positive results from our BroADen Phase 1b clinical trial of KT-621, our investigational, first-in-class, oral STAT6 degrader, in patients with moderate to severe atopic dermatitis. The data provide a powerful validation of our industry-leading STAT6 degrader program and help accelerate our goal to deliver novel oral medicines to millions of patients around the world. Our deepest thanks to the patients, investigators, and the incredible Kymera team whose dedication made this significant milestone possible. Read more about the promising KT-621 data in our press release and join our live video webcast at 8:00AM ET today: #RevolutionizingImmunology
Kymera Therapeutics15,395 次观看 • 9 个月前
没有更多内容可加载